Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules …

L Lisi, PM Lacal, M Martire, P Navarra… - Pharmacological …, 2022 - Elsevier
The immune checkpoint cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is an
inhibitory regulator of T-cell mediated responses that has been investigated as target of …

[HTML][HTML] Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis

NA Bosma, MT Warkentin, CL Gan, S Karim… - European urology open …, 2022 - Elsevier
Context Considerable advances have been made in the first-line treatment of metastatic
renal cell carcinoma (mRCC), with immunotherapy-based combinations including …

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open …

RJ Motzer, T Powles, M Burotto, B Escudier… - The Lancet …, 2022 - thelancet.com
Background In the primary analysis of CheckMate 9ER, nivolumab plus cabozantinib
showed superior progression-free survival, overall survival, and objective response over …

Nivolumab in combination with stereotactic body radiotherapy in pretreated patients with metastatic renal cell carcinoma. Results of the phase II NIVES study

C Masini, C Iotti, U De Giorgi, RS Bellia, S Buti… - European Urology, 2022 - Elsevier
Background Nivolumab showed an overall survival (OS) benefit in pretreated metastatic
renal cell carcinoma (mRCC). The role of stereotactic body radiotherapy (SBRT) in mRCC …

[HTML][HTML] Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat?

M Catalano, G Procopio, P Sepe, M Santoni… - Pharmacology & …, 2023 - Elsevier
Over the past decade, the management of metastatic renal cell carcinoma (RCC) has
undergone rapid evolution, culminating in a significant improvement in prognosis with …

New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis

P Lombardi, M Filetti, R Falcone, R Di Bidino… - Cancer Treatment …, 2022 - Elsevier
Several first-line immune-checkpoints inhibitors (ICI) based combinations have been studied
in metastatic renal cell carcinoma (mRCC) without any direct comparison between the …

Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis

K Krawczyk, K Śladowska, P Holko… - Frontiers in …, 2023 - frontiersin.org
Objective: This study aimed to compare the safety profile of tyrosine kinase inhibitors (TKIs)
approved for use as monotherapy or combination therapy for the first-line treatment of adult …

Knowledge mapping and research hotspots of immunotherapy in renal cell carcinoma: A text-mining study from 2002 to 2021

K Liu, S Zhao, J Li, Y Zheng, H Wu, J Kong… - Frontiers in …, 2022 - frontiersin.org
Background Renal cell carcinoma (RCC) is one of the most lethal urological malignancies,
and because early-stage RCC is asymptomatic, many patients present metastatic diseases …

Characterization of neuroendocrine regulation-and metabolism-associated molecular features and prognostic indicators with aid to clinical chemotherapy and …

B Zhang, Q Yuan, B Zhang, S Li, Z Wang… - Frontiers in …, 2023 - frontiersin.org
The worldwide prevalence of pancreatic cancer has been rising in recent decades, and its
prognosis has not improved much. The imbalance of substance and energy metabolism in …

Theranostic applications of glycosaminoglycans in metastatic renal cell carcinoma

SH Hua, M Viera, GW Yip, BH Bay - Cancers, 2022 - mdpi.com
Simple Summary Glycosaminoglycans (GAGs) are a class of carbohydrates that has been
closely associated with cancer progression. GAGs have been implicated in cancer cell …